Veriheal
AUGUST 12, 2021
Patients who suffer from epilepsy , which affects some 3.4 This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. CBD, which constitutes a $2,770.8
Cannabis Law Report
JANUARY 18, 2022
(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders, and anti-viral indications, reported positive results of four preclinical dermal safety studies for Epoladerm™ (diclofenac epolamine). Media: Laura Radocaj. Christopher M. Chipman, CPA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 26, 2019
The FDA also published a revised Consumer Update detailing safety concerns about CBD products more broadly. This includes ongoing work to obtain and evaluate information to address outstanding questions related to the safety of CBD products, while maintaining the agency’s rigorous public health standards.
Cannabis Law Report
JANUARY 27, 2020
We take a look at where CBD regulation might be going and whether we should be concerned about safety writes Rob Verkerk PhD, scientific and executive director, ANH-Intl. We take a look at where CBD regulation might be going and whether we should be concerned about safety. A new ‘problem’: safety. ? A new ‘problem’: safety.
Project CBD
FEBRUARY 28, 2023
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. Epilepsy Behav.
Cannabis Law Report
MAY 6, 2022
The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Since 2015, the FDA has sent warning letters to companies allegedly illegally selling unapproved cannabinoid (CBD) products.
Cannabis Law Report
AUGUST 21, 2019
The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. This would answer questions about safety and efficacy, they said.
Expert insights. Personalized for you.
66 
Let's personalize your content